These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 17293014

  • 1. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
    Shaila MS, Nayak R, Prakash SS, Georgousakis M, Brandt E, McMillan DJ, Batzloff MR, Pruksakorn S, Good MF, Sriprakash KS.
    Vaccine; 2007 May 04; 25(18):3567-73. PubMed ID: 17293014
    [Abstract] [Full Text] [Related]

  • 2. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N, Olive C, Pruksachatkunakorn C, Pruksakorn S.
    BMC Microbiol; 2006 Aug 09; 6():71. PubMed ID: 16895610
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ, Georgousakis MM, Vu T, Henningham A, Hofmann A, Rettel M, Hafner LM, Sriprakash KS, McMillan DJ.
    Vaccine; 2012 Mar 09; 30(12):2197-205. PubMed ID: 22265945
    [Abstract] [Full Text] [Related]

  • 4. Mapping a conserved conformational epitope from the M protein of group A streptococci.
    Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, Pruksakorn S, Currie B, Saul A, Good MF.
    Pept Res; 1996 Mar 09; 9(1):12-20. PubMed ID: 8727479
    [Abstract] [Full Text] [Related]

  • 5. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
    Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS.
    Vaccine; 2009 Nov 12; 27(48):6799-806. PubMed ID: 19729086
    [Abstract] [Full Text] [Related]

  • 6. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB, Smeesters PR, Courtney HS, Penfound TA, Hohn CM, Smith JC, Baudry JY.
    Vaccine; 2017 Jan 03; 35(1):19-26. PubMed ID: 27890396
    [Abstract] [Full Text] [Related]

  • 7. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C, Clair T, Yarwood P, Good MF.
    Vaccine; 2002 Jun 21; 20(21-22):2816-25. PubMed ID: 12034109
    [Abstract] [Full Text] [Related]

  • 8. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
    Aranha MP, Penfound TA, Spencer JA, Agarwal R, Baudry J, Dale JB, Smith JC.
    J Biol Chem; 2020 Mar 20; 295(12):3826-3836. PubMed ID: 32029479
    [Abstract] [Full Text] [Related]

  • 9. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
    Guerino MT, Postol E, Demarchi LM, Martins CO, Mundel LR, Kalil J, Guilherme L.
    Vaccine; 2011 Oct 26; 29(46):8250-6. PubMed ID: 21907752
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, Toth I.
    J Med Chem; 2012 Oct 11; 55(19):8515-23. PubMed ID: 22974133
    [Abstract] [Full Text] [Related]

  • 11. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
    Simerska P, Abdel-Aal AB, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, Olive C, Good MF, Toth I.
    J Med Chem; 2008 Mar 13; 51(5):1447-52. PubMed ID: 18278857
    [Abstract] [Full Text] [Related]

  • 12. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF.
    Vaccine; 2005 Mar 18; 23(17-18):2298-303. PubMed ID: 15755615
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB.
    Clin Infect Dis; 2005 Oct 15; 41(8):1114-22. PubMed ID: 16163629
    [Abstract] [Full Text] [Related]

  • 14. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I.
    J Med Chem; 2004 Jul 29; 47(16):4100-4. PubMed ID: 15267249
    [Abstract] [Full Text] [Related]

  • 15. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK, Sekhar S, Dhanda V, Toor D, Kumar R, Chakraborti A.
    J Microbiol Immunol Infect; 2016 Jun 29; 49(3):352-8. PubMed ID: 25087198
    [Abstract] [Full Text] [Related]

  • 16. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.
    J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479
    [Abstract] [Full Text] [Related]

  • 17. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP, Wibowo N, Connors NK, Wu Y, Hughes FK, Batzloff MR, Lua LH, Middelberg AP.
    Biotechnol Bioeng; 2014 Jun 01; 111(6):1062-70. PubMed ID: 24338691
    [Abstract] [Full Text] [Related]

  • 18. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
    Sandin C, Carlsson F, Lindahl G.
    Mol Microbiol; 2006 Jan 01; 59(1):20-30. PubMed ID: 16359315
    [Abstract] [Full Text] [Related]

  • 19. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA.
    Vaccine; 2007 Feb 26; 25(10):1789-97. PubMed ID: 17229503
    [Abstract] [Full Text] [Related]

  • 20. Recombinant tetravalent group A streptococcal M protein vaccine.
    Dale JB, Chiang EY, Lederer JW.
    J Immunol; 1993 Aug 15; 151(4):2188-94. PubMed ID: 8345202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.